Cangene names James Sedor CEO
This article was originally published in Scrip
Cangene Corporation, a biopharmaceutical company focused on speciality plasma products, has appointed John Sedor president and chief executive officer, and a member of the board of directors. Mr Sedor will join Cangene on 12 September, taking over from chief financial officer Michael Graham, who has been serving as interim CEO. Mr Sedor most recently served as president, CEO and director of CPEX Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.